OBJECTIVES: To compare adverse event rates and hospitalizations among metastatic breast cancer (mBC) patients initiating solvent-based (sb)-paclitaxel or albumin–bound paclitaxel (nab-P) in a large insured US population.     METHODS: Adult women with ≥2 medical claims with breast cancer diagnosis and ≥1 medical claim for secondary malignant neoplasm diagnosis initiating sb-paclitaxel or nab-P between January 1, 2010 and January 31, 2015 were selected from the Truven Health MarketScan Research Databases. Patients were required to be continuously enrolled in their health plans for ≥12 months prior to and 6 months following the treatment initiation (index date) and to remain on their index therapy for ≥2 months. Logistic regression controlling for baseline resource utilization, clinical characteristics, and adjunctive treatment was used to describe risk of inpatient admissions and adverse events (hypersensitivity, neutropenia/thrombocytopenia, anemia, and infection) between nab-P and sb-paclitaxel post-index.   RESULTS: